Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.40 |
| ▸ | YAP1 | P46937 | 1/20 | 0.40 |
| ▸ | COMT | P21964 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | TEK | Q02763 | 1/20 | 0.39 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25341214 | 0.86 | ALPL (0.48) | LMNAARTNNI3KALOX5APFEN1 | |
| SCHEMBL30519308 | 0.86 | TNNI3K (0.42) | LMNAARTNNI3KTRPV1ALOX5AP | |
| SCHEMBL25342073 | 0.86 | TNNI3K (0.42) | LMNAARTNNI3KTRPV1ALOX5AP | |
| SCHEMBL25974134 | 0.83 | TNNI3K (0.50) | TNNI3KTRPV1EPHX2TEAD1YAP1 | |
| SCHEMBL25342234 | 0.81 | ALOX5AP (0.41) | TNNI3KTRPV1ALOX5APFEN1FTO | |
| SCHEMBL25974137 | 0.81 | TRPV1 (0.49) | TRPV1EPHX2 | |
| SCHEMBL25974136 | 0.81 | EPHX2 (0.48) | TRPV1EPHX2 | |
| SCHEMBL25974054 | 0.77 | TRPV1 (0.44) | LMNAARTRPV1EPHX2POLB | |
| SCHEMBL25974055 | 0.74 | EPHX2 (0.46) | LMNATRPV1EPHX2COMT | |
| SCHEMBL25341064 | 0.73 | TRPV1 (0.50) | LMNATRPV1EPHX2KDRTEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023146513-A1 | COMPOUNDS AND METHODS OF USE THEREOF | VIVACE THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146513-A1 | COMPOUNDS AND METHODS OF USE THEREOF | VIVACE THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |